JP2002531490A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531490A5
JP2002531490A5 JP2000586308A JP2000586308A JP2002531490A5 JP 2002531490 A5 JP2002531490 A5 JP 2002531490A5 JP 2000586308 A JP2000586308 A JP 2000586308A JP 2000586308 A JP2000586308 A JP 2000586308A JP 2002531490 A5 JP2002531490 A5 JP 2002531490A5
Authority
JP
Japan
Prior art keywords
nerve
agent
fgf
brain
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/029335 external-priority patent/WO2000033814A2/en
Publication of JP2002531490A publication Critical patent/JP2002531490A/ja
Publication of JP2002531490A5 publication Critical patent/JP2002531490A5/ja
Pending legal-status Critical Current

Links

JP2000586308A 1998-12-09 1999-12-09 中枢神経系に薬剤を投与するための方法 Pending JP2002531490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20853998A 1998-12-09 1998-12-09
US09/208,539 1998-12-09
PCT/US1999/029335 WO2000033814A2 (en) 1998-12-09 1999-12-09 Method for administering agents to the central nervous system

Publications (2)

Publication Number Publication Date
JP2002531490A JP2002531490A (ja) 2002-09-24
JP2002531490A5 true JP2002531490A5 (cg-RX-API-DMAC10.html) 2006-12-14

Family

ID=22774961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586308A Pending JP2002531490A (ja) 1998-12-09 1999-12-09 中枢神経系に薬剤を投与するための方法

Country Status (6)

Country Link
EP (1) EP1135105B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002531490A (cg-RX-API-DMAC10.html)
AT (1) ATE289800T1 (cg-RX-API-DMAC10.html)
AU (1) AU2173400A (cg-RX-API-DMAC10.html)
DE (1) DE69923998T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000033814A2 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1602378A1 (en) * 1999-12-09 2005-12-07 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
CA2597525A1 (en) * 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
RS59490B1 (sr) 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
WO2016085787A1 (en) * 2014-11-25 2016-06-02 Corning Incorporated Cell culture media extending materials and methods
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
WO2017017543A1 (en) * 2015-07-30 2017-02-02 U R Anoop Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
EP3509585B1 (en) * 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200757B1 (en) * 1984-10-19 1992-03-11 Chiron Corporation Promotion of wound healing with human epidermal growth factor prepared from recombinant dna
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale

Similar Documents

Publication Publication Date Title
US7273618B2 (en) Method for administering agents to the central nervous system
EP1135105B1 (en) Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
EP1137401B1 (en) Administration of neurotrophic agents to the central nervous system
US20020169102A1 (en) Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6313093B1 (en) Method for administering insulin to the brain
CN1181885C (zh) 中枢神经系统局部缺血或损伤后多肽生长因子的给药
JP7756953B2 (ja) マグネシウム含有オキシトシン製剤および使用の方法
US6407061B1 (en) Method for administering insulin-like growth factor to the brain
US20040115587A1 (en) Methods and systems for enabling and stabilizing tooth movement
JP2003516360A (ja) 中枢神経系およびリンパ系に対するサイトカイン投与方法
JPH09509140A (ja) 神経学的障害の治療方法
CA2516857A1 (en) Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans
US20210130445A1 (en) CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
GB2414934A (en) Treatment of Parkinson's disease with GDNF
JP2011506413A (ja) 瘢痕化阻害の方法
JP2004527461A (ja) 中枢神経系に影響を与える虚血性事象を治療する方法